Literature DB >> 2083555

Mouse-specific antibody responses to a monoclonal antibody during repeated immunoscintigraphy investigations: comparison of antibody titres and imaging studies in a rat model.

M V Pimm1, A C Perkins, S J Gribben, A J Markham.   

Abstract

As a model for human mouse-specific antibody responses in patients undergoing immunoscintigraphy, we have investigated in rats the production of mouse-specific antibodies (MA) to the mouse monoclonal antibody 791T/36. At intervals of between 5 and 16 weeks the rats were given repeated cycles of intravenous (IV) injections of antibody with or without a simultaneous intradermal (ID) injection. The IV dose was 60 micrograms/kg, a dose similar to that used in many clinical immunoscintigraphy studies. The ID injection was 2 micrograms, which mimicks the skin test dose often given in clinical imaging protocols. The study was carried out with both 131I-labelled antibody and with antibody labelled with 111In by diethylenetriamine-penta-acetic acid (DTPA) chelation. MA was measured with a passive haemagglutination assay using sheep red blood cells coated with the monoclonal antibody. Of rats given ID injections of unlabelled antibody at the same time as the IV imaging doses, 9/20 produced MA during 4 cycles of injections. In contrast, only 2/16 rats given only the IV dose produced MA. Both 131I- and 111In-labelled antibody appeared equally immunogenic with 5/18 and 6/18 overall responders, respectively. The production of MA was associated with a significant perturbation in the biodistribution of the IV dose of labelled antibody as seen by gamma-camera imaging of the rats given 111In-labelled antibody. There was clearance of immune complexes to the liver, this organ accumulating up to 90% of the whole body count rate of radiolabel. MA titres of between 1/100 and 1/78,000 caused equal perturbation of biodistribution, although below 1/100 the effect was more variable.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2083555     DOI: 10.1007/BF00812360

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  15 in total

Review 1.  Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases.

Authors:  M J Van Kroonenburgh; E K Pauwels
Journal:  Nucl Med Commun       Date:  1988-11       Impact factor: 1.690

2.  Abrogation of antibody responses in rats to murine monoclonal antibody 791T/36 by treatment with daunomycin-cis-aconityl-791T/36 conjugates.

Authors:  L G Durrant; R A Robins; R A Marksman; M C Garnett; Y Ogunmuyiwa; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients.

Authors:  M V Pimm; A C Perkins; N C Armitage; R W Baldwin
Journal:  J Nucl Med       Date:  1985-09       Impact factor: 10.057

4.  In vivo localization of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts.

Authors:  M V Pimm; M J Embleton; A C Perkins; M R Price; R A Robins; G R Robinson; R W Baldwin
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

5.  Imaging of melanoma with L-131-labeled monoclonal antibodies.

Authors:  S M Larson; J P Brown; P W Wright; J A Carrasquillo; I Hellström; K E Hellström
Journal:  J Nucl Med       Date:  1983-02       Impact factor: 10.057

6.  Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma.

Authors:  A G Siccardi; G L Buraggi; L Callegaro; G Mariani; P G Natali; A Abbati; M Bestagno; V Caputo; L Mansi; R Masi
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

7.  Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments.

Authors:  G L Buraggi; L Callegaro; G Mariani; A Turrin; N Cascinelli; A Attili; E Bombardieri; G Terno; G Plassio; M Dovis
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

8.  Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments.

Authors:  J A Carrasquillo; K A Krohn; P Beaumier; R W McGuffin; J P Brown; K E Hellström; I Hellström; S M Larson
Journal:  Cancer Treat Rep       Date:  1984-01

9.  The implications of patient antibody response for the clinical usefulness of immunoscintigraphy.

Authors:  A C Perkins; M V Pimm; M C Powell
Journal:  Nucl Med Commun       Date:  1988-04       Impact factor: 1.690

10.  A comparative study of the relative sensitivity and specificity of radiolabelled monoclonal antibody and computerised tomography in the detection of sites of disease in human malignant melanoma.

Authors:  A T Elliott; R M MacKie; T Murray; V R Doherty; F G Adams
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.